Download PDF

Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years

This is a temporary file and hence do not link it from a website, instead link the URL of this page if you wish to link the PDF file.
To read this article you will require Adobe© Acrobat Reader, if you do not have this installed you can download it from here

Support open access Recommend